Millennium Pharmaceuticals, Inc. has made executive appointments and several key promotions. Christophe Bianchi, M.D. will join the company as executive vice president for commercial operations. He will also be an executive officer of the company and a member of the leadership team. Mark Kost has been named vice president, finance. Grant Bogle has been promoted to senior vice president, sales and marketing and Elizabeth Lewis, Esq. has been promoted to vice president, commercial law. The company has also appointed Anna Protopapas, senior vice president, corporate development, as an executive officer and a member of the leadership team.

Dr. Bianchi, with 17 years of experience in the U.S. Pharma industry, joined the company from Sanofi-Aventis, where he led the U.S. oncology business unit, a $2 billion business with blockbuster brands such as Eloxatin and Taxotere. Previously, he headed Sanofi’s internal medicine, CNS and oncology U.S. business unit. Dr. Bianchi also had a successful 10-year career at Rhone-Poulenc Rorer, most recently serving as vice president and head of global marketing.

Mr. Kost joined the company from Gillette where he served as vice president of finance for global technology and manufacturing group. He was responsible for more than $4 billion in annual spend in global manufacturing, R&D, supply chain, new product development and engineering organizations, as well as the global real estate portfolio. Prior to joining Gillette, Mr. Kost held executive finance positions at Polaroid, FosterGrant, and Pepsico, and has more than 20 years of corporate finance experience.

Mr. Bogle has been promoted to senior vice president, sales and marketing for Velcade for Injection. Since June 2005, he has been responsible for the overall marketing and sales strategy for Velcade. He joined Millennium in 2004 as the head of sales and marketing for Integrilin Injection, a product the company sold the development and commercial rights to Schering-Plough in 2005. Mr. Bogle has broad sales management and marketing experience from BASF Pharma (Knoll Pharmaceuticals) and Roche, and hospital experience from American Critical Care and Dupont. Prior to joining Millennium, Mr. Bogle was president of ViaCord.

Ms. Lewis has played a critical role in the launch of Velcade and has worked closely with senior leadership within the commercial organization to support the continued growth of the product. Ms. Lewis joined Millennium in 2002. Prior to joining the company, she was a partner in the firm of Epstein Becker & Green and co-chaired the firm’s pharmaceutical health regulatory practice group.

Since Ms. Protopapas joined Millennium in 1997, she has led many of the company’s efforts in strategic alliances, product acquisitions, out-licensing and new ventures. During her tenure, she has been a key driver in forging partnerships that have generated significant revenue and value for the company, including collaborations with Johnson & Johnson Pharmaceuticals R&D L.L.C., Aventis Pharmaceuticals and Abbott Laboratories. Under her leadership, Millennium has built a strong business development team with significant industry experience.